Erratum to “The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs)” [Eur. J. Obstet. Gynecol. Reprod. Biol. 179 (2014) 32–35]

AbstractBackground:Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate-specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS.Methods:We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth- generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA.Results:cPSA and fPSA levels were about three times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to waist-to-hip ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% confidence interval [CI]: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-the-receiver-operating-characteristic curve of 0.89.Conclusions:Serum cPSA and fPSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

Download Full-text

Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome – a new insight

Gynecological Endocrinology ◽

10.1080/09513590.2016.1200552 ◽

2016 ◽

Vol 32 (11) ◽

pp. 931-935 ◽

Cited By ~ 3

Author(s):

Ewa Rudnicka ◽

Stanislaw Radowicki ◽

Katarzyna Suchta

Keyword(s):

Prostate Specific Antigen ◽

Polycystic Ovarian Syndrome ◽

Specific Antigen ◽

Ovarian Syndrome

Download Full-text

Prostate Specific Antigen: A Diagnostic Marker in Polycystic Ovarian Syndrome

JOURNAL FOR CLINICAL AND DIAGNOSTIC RESEARCH ◽

10.7860/jcdr/2019/38177.12500 ◽

2019 ◽

Author(s):

Kiran Bhat ◽

Meena Bhandari ◽

Vaishali Garg

Keyword(s):

Prostate Specific Antigen ◽

Polycystic Ovarian Syndrome ◽

Diagnostic Marker ◽

Specific Antigen ◽

Antigen A ◽

Ovarian Syndrome

Download Full-text

Role of insulin sensitising agents in altering PSA level in PCOS

International Journal of Reproduction Contraception Obstetrics and Gynecology ◽

10.18203/2320-1770.ijrcog20175013 ◽

2017 ◽

Vol 6 (11) ◽

pp. 4986 ◽

Cited By ~ 2

Author(s):

Rajashree Panigrahy ◽

Bratati Singh ◽

Tapan K. Pattnaik ◽

Sanjukta Misra

Keyword(s):

Insulin Resistance ◽

Polycystic Ovarian Syndrome ◽

Specific Antigen ◽

Serum Testosterone ◽

Healthy Controls ◽

Androgen Excess ◽

Control Serum ◽

Ovarian Syndrome ◽

Significant Concentration

Background: Ovarian androgen production can be promoted by insulin resistance which leads to reproductive abnormalities in Polycystic Ovarian Syndrome (PCOS). A wide variety of female tissues can synthesize and secrete Prostate Specific Antigen (PSA). Androgens may take part a significant role in PSA secretion in PCOS. As insulin resistance stimulates androgen production, the baseline value of PSA may decline by insulin sensitising agents in PCOS. Present study is an attempt to measure the function of PSA as a marker of androgen excess in PCOS and to assess the role of insulin sensitising agent metformin in altering PSA level in PCOS.Methods: The study was undertaken to assess the insulin resistance, testosterone and PSA level in 45 women diagnosed as PCOS and 45 healthy controls. Alteration of insulin resistance, serum testosterone and PSA levels by metformin was also analysed.Results: A significant increase in testosterone, PSA level and insulin resistance was observed in PCOS cases when compared with control (p<0.001). When metformin was given for 4 months, improvement in insulin resistance and testosterone level was found in cases, but PSA values observed no change. Correlation was not found linking insulin resistance with PSA level prior to and after therapy.Conclusions: Serum PSA level could be detected in high significant concentration in PCOS women. Various researches explain that insulin resistance and BMI may perhaps control serum PSA level, but our result demonstrate no effect of insulin sensitising agent on serum PSA value.

Download Full-text

Diagnostic accuracy of prebiopsy Ga-68 PSMA PET/CT in detecting primary prostate carcinomas with prostate-specific antigen <50 ng/ml

Indian Journal of Nuclear Medicine ◽

10.4103/ijnm.ijnm_81_20 ◽

2020 ◽

Vol 35 (4) ◽

pp. 283

Author(s):

Piyush Chandra ◽

Shanmugasundaram Rajaian ◽

Karrthik Krishnamurthy ◽

Lakshman Murugasen ◽

Ganesan Chandran ◽

...

Keyword(s):

Diagnostic Accuracy ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Psma Pet ◽

Pet Ct ◽

Prostate Carcinomas

Download Full-text

Relationship of Prostate Specific Antigen and Digital Rectal Examination in the Prediction of Prostate Cancer

Journal of College of Medical Sciences-Nepal ◽

10.3126/jcmsn.v16i2.29122 ◽

2020 ◽

Vol 16 (2) ◽

pp. 83-87

Author(s):

Bhusan Raj Timilsina ◽

Gaurav Devkota ◽

Shweta Giri ◽

Sulav Pradhan ◽

Sudeep RaJ KC

Keyword(s):

Prostate Cancer ◽

Diagnostic Accuracy ◽

Prostate Specific Antigen ◽

Specific Antigen ◽

Digital Rectal Examination ◽

Cross Sectional Study ◽

Medical Sciences ◽

Cross Sectional ◽

Rectal Examination ◽

Relationship Of

Background: Prostate cancer is one of the most common and leading cause of death among different genitourinary causes. However, screening of prostate cancer is limited to Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) in Nepal. The aim of this study is to find out which modality is more helpful for the diagnosis of Prostate Cancer. Methods: A retrospective cross-sectional study was conducted in the department of Urology, College of Medical Sciences, Chitwan, Nepal. All patients included in this study were who presented to the OPD with Lower Urinary Tract Symptoms (LUTS). The patients were above the age of 40 with clinical suspicion prostate cancer based on either DRE or PSA. Results: A total of 150 patients were enrolled from April 2019 to April 2020. Their mean± SD age was of 65.18±9.38 years. The accuracy of the diagnostic test for DRE and PSA were cut off at 4, PSA cut off range of 4 to 10, PSA cut off range of 10 to 30 and PSA cut off at 30 showed that all the screening indices were better for DRE (Sensitivity=100%, Specificity=59.2%, Diagnostic Accuracy=62.2%) than for PSA cut off at 4 (Sensitivity=100%, Specificity=27.6%, Diagnostic Accuracy=32.9%). Among various cut off score or ranges for PSA, cut off score at 30 provided the best screening indices with Sensitivity of 66.7%, Specificity of 97.4% and Diagnostic Accuracy of 95.1%. Conclusions: PSA has higher diagnostic accuracy then DRE. Keywords: DRE; LUTS; Prostate cancer; PSA.

Download Full-text

The Proportion of Prostate-specific Antigen (PSA) Complexed to α1-Antichymotrypsin Improves the Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia in Men with a Total PSA of 10 to 30 μg/L

Clinical Chemistry ◽

10.1093/clinchem/48.8.1251 ◽

2002 ◽

Vol 48 (8) ◽

pp. 1251-1256 ◽

Cited By ~ 10

Author(s):

Manuel Martínez ◽

Francisco España ◽

Montserrat Royo ◽

José M Alapont ◽

Silvia Navarro ◽

...

Keyword(s):

Prostate Cancer ◽

Benign Prostatic Hyperplasia ◽

Confidence Interval ◽

Diagnostic Accuracy ◽

Prostate Specific Antigen ◽

Correct Diagnosis ◽

Specific Antigen ◽

Prostatic Hyperplasia ◽

Total Psa ◽

L 14

Abstract Background: The aim of this study was to assess the diagnostic accuracy of the proportion of prostate-specific antigen (PSA) complexed to α1-antichymotrypsin (PSA-α1ACT:PSA ratio) in the differential diagnosis of prostate cancer (CaP) and benign prostatic hyperplasia (BPH) in men with total PSA of 10–30 μg/L. Methods: We used our immunoassays (ELISAs) for total PSA and PSA-α1ACT complex to study 146 men. In 123, total PSA was between 10 and 20 μg/L; 66 of these had CaP and 57 BPH. In 23 men, total PSA was between 20 and 30 μg/L; 14 of these had CaP and 9 BPH. We calculated the area under the ROC curves (AUC) for total PSA, PSA-α1ACT complex, and PSA-α1ACT:PSA ratio, and determined the cutoff points that gave sensitivities approaching 100%. Results: In the total PSA range between 10 and 20 μg/L, the AUC was significantly higher for the PSA-α1ACT:PSA ratio (0.850) than for total PSA (0.507) and PSA-α1ACT complex (0.710; P <0.0001). A cutoff ratio of 0.62 would have permitted diagnosis of all 66 patients with CaP (100% sensitivity) and avoided 19% of unnecessary biopsies (11 of 57 patients). In the total PSA range between 20 and 30 μg/L, the AUC for the PSA-α1ACT:PSA ratio (0.980; 95% confidence interval, 0.82–0.99) was greater than the AUC for total PSA (0.750; 95% confidence interval, 0.51–0.89; P = 0.042). In this range, a cutoff point of 0.64 would have permitted the correct diagnosis of all 14 patients with CaP and 6 of the 9 with BPH. Conclusions: The diagnostic accuracy of the PSA-α1ACT:PSA ratio persists at high total PSA concentrations, increasing the specificity of total PSA. Prospective studies with large numbers of patients are needed to assess whether the ratio of PSA-α1ACT to total PSA is a useful tool to avoid unnecessary prostatic biopsy in patients with a total PSA >10 μg/L.

Download Full-text